- 1 **Title:** Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium
- 2 pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy:
- 3 Results of an open-label, prospective, exploratory clinical study
- 4 **Running Title**: N-163 beta glucan as disease modifying agent in DMD
- 5 Authors:
- 6 Kadalraja Raghavan^{1,,2,3} (<u>drkraghavan@nichimail.jp</u>)
- 7 Vidyasagar Devaprasad Dedeepiya⁴ (<u>drddp@nichimail.jp</u>)
- 8 Subramaniam Srinivasan⁴ (masala76@gmail.com)
- 9 Subramanian Pushkala⁵ (<u>pushkala66m@gmail.com</u>)
- 10 Sudhakar Subramanian⁶ (drsudhakar77@gmail.com)
- 11 Nobunao Ikewaki^{7,8} (nikewaki@phoenix.ac.jp)
- 12 Masaru Iwasaki⁹ (miwasaki@yamanashi.ac.jp)
- 13 Rajappa Senthilkumar¹⁰ (rsk@nichimail.jp)
- 14 Senthilkumar Preethy¹⁰ (<u>drspp@nichimail.jp</u>)
- 15 Samuel JK Abraham^{4,9,11} (<u>drsam@nichimail.jp</u>)
- 16 Affiliations:
- 1. Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for
- Advanced Recovery and Education (JAICARE), Madurai, India
- 19 2. Department of Paediatric Neurology, Kenmax Medical Service Private Limited,
- 20 Madurai, India.
- 3. Department of Paediatric Neurology, Sarvee Integra Private Limited, Chennai, India.

- 4. Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative
- 23 Medicine (NCRM), Chennai, India.
- 5. Department of Immunology, The Tamil Nadu Dr. M.G.R. Medical University,
- 25 Chennai, 600032, India.
- 6. Department of Anesthesia and Pain service, Toronto Western Hospital, 399 Bathurst
- 27 street Toronto, Ontario, Canada.
- 7. Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
- 29 8. Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
- 9. Centre for Advancing Clinical Research (CACR), University of Yamanashi School
- of Medicine, Chuo, Japan.
- 32 10. Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine
- 33 (NCRM), Chennai, India.
- 34 11. Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu,
- 35 Japan

36 Corresponding author information:

- 37 Dr. Samuel JK Abraham,
- 38 II Department of Surgery & CACR,
- 39 University of Yamanashi, Faculty of Medicine
- 40 Address for correspondence: 3-8, Wakamatsu, Kofu, 400-0866, Yamanashi, Japan
- Email id- <u>drsam@nichimail.jp</u>; Alternate email id: <u>drspp@nichimail.jp</u>
- 42 Fax: +81-55-235-7569

43

Declarations:

45

46

49

50

Ethics approval and consent to participate

47 The study was registered in Clinical trials registry of India, CTRI/2021/05/033346.

48 Registered on 5th May, 2021. The study was approved by the Institutional Ethics Committee

(IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.

Consent for publication

Not applicable

52 Availability of data and material

All data generated or analysed during this study are included in the article itself.

54 Funding

No external funding was received for the study

Competing interests

Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of novel beta glucans using different strains of Aureobasidium pullulans and also an applicant to several patents of relevance to these beta glucans.

Authors' contributions

57 KR, NI and SA. contributed to conception and design of the study. KR, RS and NI helped in

data collection and analysis. SA and SP drafted the manuscript. VD, SS, SUP, SSU and MI

performed critical revision of the manuscript. All authors read and approved the final

3

manuscript.

56

58

59

60

Acknowledgements

62

63

- 64 The authors would like to dedicate this paper to the memory of Mr. Takashi Onaka, who
- 65 passed away on the 1st of June, 2022 at the age of 90 years, who played an instrumental role
- 66 in successfully culturing an industrial scale up of AFO-202 and N-163 strains of
- 67 Aureobasidium pullulans after their isolation by Prof. Noboru Fujii, producing the novel beta
- 68 glucan described in this study.
- 69 They thank
- 70 1. The Government of Japan and the Prefectural Government of Yamanashi for a special
- 71 loan and M/s Yamanashi Chuo Bank for processing the transactions.
- 72 2. Ms. Sunitha, Mr. Vincent, Mr. Shivakumar (Physiotherapist), Dr. Madhankumar and
- 73 the staff of Kenmax & Sarvee Integra, for their assistance during the clinical study and data
- 74 collection of the manuscript.
- 75 3. Fr. Francis Xavier, Fr. Vargheesh Antony, Fr. Marianathan and Mr Jeyachandran of
- 76 JAICARE for their support during the clinical study.
- 77 4. Mr. Mitsuru Nagataki (Sophy Inc, Kochi, Japan), for necessary technical
- 78 clarifications.
- 79 5. Mr. Yoshio Morozumi and Ms. Yoshiko Amikura of GN Corporation, Japan for their
- liaison assistance with the conduct of the study.
- 81 6. Loyola-ICAM College of Engineering and Technology (LICET) for their support to
- 82 our research work.

83

84

85

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

Abstract **Background:** This trial is to evaluate the effects of supplementation of Aureobasidium pullulans-N-163 strain produced 1,3-1,-6 beta glucan in young patients with Duchenne muscular dystrophy (DMD). **Methods:** Twenty-seven male subjects aged 5-19 years with DMD were included, nine in the control arm and 18 in the treatment arm to receive N-163 beta glucan along with conventional therapies for 45 days. While performing the analysis, patients were stratified into: those not administered steroids (Steroid -ve) (Control, n=5; treatment, n=9), those administered steroids (Steroid +ve) (Control, n=4; treatment, n=9), which was not pre-specified. **Results:** IL-6 showed a significant decrease in the N-163 Steroid -ve group, from 7.2 ± 1.2 pg/ml to 2.7 ± 0.03 pg/ml. IL-13 decreased in both treatment groups—from 157.76 ± 148.68 pg/ml to $114.08 \pm 81.5 \text{ pg/ml}$ (N-163 Steroid -ve) and from $289.56 \pm 232.88 \text{ pg/ml}$ to 255.56 ± 214.13 pg/ml (N-163 Steroid +ve). TGF-β levels showed a significant decrease in the N-163 Steroid -ve group. Dystrophin levels increased by up to 32% in both treatment groups. Medical research council (MRC) grading showed slight improvement in muscle strength improvement in 12 out of 18 patients (67%) in the treatment group and four out of nine (44%) subjects in the control group. **Conclusion:** Supplementation with the N-163 beta glucan food supplement produced beneficial effects: a significant decrease in inflammation and fibrosis markers, increase in serum dystrophin and

slight improvement in muscle strength in DMD subjects over 45 days, thus making this a potential adjunct treatment for DMD after validation. Trial registration: The study was registered in Clinical trials registry of India, CTRI/2021/05/033346. Registered on 5th May, 2021. **Keywords:** Duchenne muscular dystrophy; N-163; beta glucan; disease modifying agent; inflammation; fibrosis; dystrophin **Introduction:**

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder causing severe and progressive weakness of skeletal muscles, leading to loss of ambulation along with concomitant impairment of cardiac and respiratory muscles and early mortality. Mutations in the dystrophin gene, which cause total loss of the dystrophin protein [2], remain the major underlying mechanism. Loss of dystrophin leads to damage of the myofibres' plasma membranes and distorts the structural stability of the plasma, leading to weakness in the myofibres. The weakened myofibres cannot withstand the contraction and relaxation cycles occurring during muscle function. The damage to the membrane releases the cytoplasmic contents, triggering the immune system and causing further muscle fibre damage, weakness and ultimately death [3]. A chronic proinflammatory state ensues, with neutrophil infiltration and macrophages' phagocytosis of the degenerated tissue [3], preventing repair of the muscle damage, which otherwise occurs in a highly orchestrated manner for faster repair in other physiological conditions. The muscle is relatively immunologically privileged, with a low capacity to generate localized immune responses and thus having low rates of abscess and granuloma formation [3]. Therefore, it becomes essential to modulate the inflammation and immunity to resolve the chronic inflammatory state in therapeutic approaches to DMD. Steroid therapy is the most commonly employed immuno-modulatory treatment approach. However, side effects include weight gain, weak bones, high blood pressure and behaviour changes in addition to muscle weakness and atrophy in the long term [4,5]. Thus, there arises the need to develop strategies that will assist in immunomodulation with lesser side effects. Nutritional supplements are a potential option. Beside beta glucans yielding locomotor improvement in zebrafish models of DMD [6], a 1-3,1-6 beta glucan from the N-163 strain of the black yeast Aureobasidium pullulans has been reported to mitigate inflammation, evident by decreases in anti-inflammatory markers such as CD11b, serum ferritin, galectin-3 and fibrinogen. It also produces beneficial immuno-

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

modulation via a decrease in the neutrophil-to-lymphocyte ratio (NLR) and an increase in the lymphocyte-to-CRP ratio (LCR) and leukocyte-to-CRP ratio (LeCR) in human healthy volunteers [7]. Mitigation of lipotoxicity-associated inflammatory cascades in a mouse study has also been reported [8]. Another study done in an animal model of non-alcoholic steatohepatitis (NASH) showed a decrease in liver inflammation and accumulation of F4/80+ cells (macrophages associated with inflammation) [9] in the liver. The present exploratory study is to evaluate the immunomodulatory efficacy of the N-163 strain of A. pullulansproduced beta 1-3,1-,6 glucan in comparison with a conventional therapeutic regimen in patients with DMD. **Methods:** This trial was an investigator-initiated, single-centre, randomized, open-label, prospective, comparative clinical study of patients with DMD. The study was conducted over 45 days. The two treatment arms included were: Treatment arm I, control arm: Conventional treatment regimen comprising standard routine physiotherapy for joint mobility along with medications, viz., T. calcium and vit. D 1000 with or without deflazacort (steroid) 6mg to 24 mg. **Treatment arm II**, intervention: One sachet of N-163 beta glucan (15g gel) once daily along with conventional treatment. The stratification based on steroid was performed only during analysis of the data and was not pre-specified. Inclusion criteria: Male subjects with molecular diagnosis of DMD aged 6-18 years who were willing to participate in the study with written informed consent.

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

Exclusion criteria: Patients with a previous (within the past 1 month) or concomitant participation in any other therapeutic trial; a known or suspected malignancy; any other chronic disease or clinically relevant limitation of renal, liver or heart function according to the discretion of the investigator. Investigations: The following tests were carried out after written consent was obtained from the study subjects. At baseline and at the end of the study (after 45 days): Background survey: gender, date of birth, age, habits, current medical history, medication, treatment, allergies (to drugs and food), regular use of food for specified health uses, functional foods, health foods, intake of foods rich in β-glucan foods containing beta-glucan and intake of immunity-boosting foods Medical history and physical measurements: height, weight, BMI, temperature Physiological examination: systolic blood pressure, diastolic blood pressure, pulse rate **ECG** Muscle strength test using MRC grading [10] Six-minute walk test (6MWT) [11] North Star Ambulatory Assessment (NSAA) [12] Blood sampling and investigations for the levels of IL-6, IL-13, TGF-β, creatinine kinase (CK), titin, haptoglobin, TNF-α, dystrophin, cystatin in the blood and myoglobin in the urine Subjects were contacted every week for drug compliance and recording of adverse effects, if any

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

Study subjects = 28The study was designed as an exploratory study, so there were two intervention conditions: one control and one test group. As the minimum number of participants required for statistical comparisons within and between intervention conditions is four per intervention condition, a total of 28 target study participants (10 in treatment arm I [control] group and 18 in treatment arm II [N-163]) were used. One patient was disqualified due to misrepresentation of diagnosis. The CONSORT flow diagram of the trial is shown in Figure 1. Selection of study subjects Study investigators and other investigators included study subjects who had consented to participate in the study, met the selection criteria and not the exclusion criteria, and who were judged to have no problem participating in the study. Allocation of study subjects The person in charge of the allocation, as specified in the study protocol, allocated the study subjects to the two groups by simple randomization (1:2). Primary outcome: Observation of changes in the levels of IL-6 in serum and myoglobin levels in urine from the baseline measured by ELISA. Secondary outcome: Observation of changes in the levels of IL-13, TGF-β, CK, titin, dystrophin, haptoglobin and cystatin C in the serum measured by ELISA. Observation of changes in the muscle function tests

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Monitoring for adverse effects ELISA: The biomarkers were validated using sandwich enzyme immunoassay. ELISA kits were purchased from different manufacturers and the assay details along with sensitivity are listed in Table 2. ELISAs were performed according to manufacturer's instructions and the serum was diluted to fall within the linear range of each respective assay. Statistical analysis: All data were analysed using Excel statistics package analysis (Microsoft Office Excel) and Origin2021b software. All 27 randomized participants were included in safety and efficacy analysis sets. All statistical tests were performed at a significance level of 0.05 without correction for multiple comparisons or multiple outcomes. Non-parametric tests such as Mann-Whitney U test and Kruskal-Wallis tests were used. **Results:** Twenty-eight patients were screened and 27 were randomized to control (n = 9) and treatment (n = 18). One patient was disqualified due to misrepresentation of diagnosis. The CONSORT flow diagram of the trial is shown in Figure 1. Demographics are shown in Table 1. The stratification of patients was as follows based on steroid administration during analysis: Group I: Control group (n = 9); A. Steroids not administered (n = 5) (Steroid -ve) B. Steroids administered (n = 4) (Steroid +ve)

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

Group II: Treatment (N-163) group (n = 18); A. Steroids not administered (n = 9) (Steroid -ve) C. Steroids administered (n = 9) (Steroid +ve) The mean \pm SD age for the total study population was 11.18 ± 3.86 years (range 5-19 years). The mean age across the groups were Control (Steroid-ve) -14.25 years; Control (Steroid +ve) – 13.6 years; N-163 (Steroid -ve) – 9.6 years; N-163 (Steroid +ve) – 11.87 years. However the difference was not statistically significant (P= 0.316). The mean \pm SD body weight was 35.59 ± 15.5 kgs (range = 10 to 65 kgs). No adverse events were reported. No clinically significant changes from baseline data were observed on physical examination or in vital signs—temperature, blood pressure, oxygen saturation, pulse rate or ECG (data not shown). Biomarker levels: Levels are expressed as mean \pm SD. In regard to the primary outcome, IL-6 showed decrease in both the control and the treatment groups. However, when the analysis was stratified for steroid administration, IL-6 showed the highest decrease in the N-163 Steroid -ve group, from a baseline value of 7.2 ± 1.2 pg/ml to 2.7 ± 0.03 pg/ ml post intervention and the difference was significant (p-value = 0.01) (Figure 2, 6). IL-13 increased in both control groups—from 300.4 ± 114.5 pg/ml at baseline to $550.732 \pm$ 107.95 pg/ml post-intervention in the Steroid -ve group and from 142 ±112.82 pg/ml at baseline to 263.5 ± 99.38 pg/ml post-intervention in the Steroid +ve group. It decreased in both the treatment groups—from 157.76 ± 148.68 pg/ml at baseline to 114.08 ± 81.5 pg/ml post-intervention and from 289.56 ± 232.88 pg/ml at baseline to 255.56 ± 214.13 pg/ml postintervention. The difference was statistically significant (p-value = 0.006) (Figure 3, 6).

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

TGF-β levels showed a significant decrease in the N-163 Steroid -ve group, from a baseline value of 3302 ± 1895 pg/ml to 1325.66 ± 517 pg/ml post intervention, which was significantly lower than all the other groups (p-value = 0.02) (Figure 4, 6). Dystrophin levels showed a significant increase in the N-163 Steroid -ve group, from a baseline value of 3.01 ± 1.58 ng/ml to 4.01 ± 1.44 ng/ml post intervention, and the N-163 Steroid +ve group went from a baseline value of 3.15 ± 2.43 ng/ml to 3.78 ± 2.17 ng/ml post intervention, which was significantly higher than the control groups (p-value = 0.0009) (Figure 5, 6). The N-163 Steroid -ve group showed higher dystrophin expression than the N-163 Steroid +ve group with the difference being significant (p-value = 0.01). The percentage increase in dystrophin levels in the treatment group was up to 32.8%. Haptoglobin did not show much difference pre or post intervention in the treatment groups, but it was marginally increased in the control group (Figure 7). CK increased in the treatment groups (Figure 7). Urine myoglobin increased in the N-163 Steroid +ve group but decreased in all the other groups (Figure 7). Titin and cystatin C decreased in the N-163 Steroid +ve group and the control Steroid +ve group, but the difference was not significant. TNF-α decreased in all the groups except the N-163 Steroid -ve group (Figure 7). The 6MWT and NSAA did not show any significant differences between the groups (Figure 8). The MRC grading showed slight improvement in 12 out of 18 patients (67%) in the treatment group and only four out of nine (44%) subjects in the control group but it was not statistically significant (p-value = 0.02) (Table 3, Figure 8). **Discussion:** Current interventions for DMD, such as corticosteroids and rehabilitative care, help to prolong survival up to the third or the fourth decade of life. Corticosteroids remain the

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

mainstream supportive approach to slow inflammation and the associated decline in muscle strength and function [4]. However, steroids have their own adverse effects, and their prescription is based on risk versus benefit to that specific patient and tolerance to the medication. Exon-skipping gene therapy and cell-based strategies to replace the mutant DMD gene are in development, but the desired outcome has not yet been achieved. In the meantime, nutraceuticals can be considered potential strategies for immune modulation and alleviating inflammation, as they are safer with lesser adverse effects [4]. Improvement of the locomotor performances and mitochondrial respiration by 1,3-1,6 beta-glucans in zebra fish model of muscular dystrophy [6] has already been reported. In the current study, we focussed on a 1-3,1-6 beta glucan from the N-163 strain of the black yeast A. pullulans that has been reported to mitigate inflammation, evidenced by a decrease in anti-inflammatory markers and production of beneficial immuno-modulation [6-8]. The safety profile of N-163 beta glucan has been confirmed by the results. **Anti-inflammatory and anti-fibrotic outcomes:** Circulating IL-6 is chronically elevated in individuals with DMD [13], which has been reported to contribute to DMD-associated cognitive dysfunction. IL-6 blockades have been advocated as a therapeutic approach for DMD [14]. In the present study, IL-6 showed highest decrease in the N-163 Steroid -ve group (Figure 2). While IL-6 is an acute inflammatory biomarker [14], IL-13 is a pro-fibrotic biomarker [15] and was significantly decreased (Figure 3). Together with the TGF-B pathway, it is a major proinflammatory and pro-fibrotic cytokine responsible for the chronic inflammatory response leading to replacement of the muscle by scar tissue or fibrosis, resulting in muscle weakness and loss of muscle function [16]. IL-6 values matched that of healthy controls and DMD patients who were treated with corticosteroids [17]. TGF-β levels also showed a significant decrease in the N-163 Steroid -ve group (Figure 4). Dystrophin restoration of 20% expression [18,19] is considered the point of efficacy for a DMD therapy

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

[20] and was found to increase by 32.8% in both the treatment groups (Figure 5) of the present study from baseline. We used serum dystrophin evaluation as recent evidence points to the fact that the lack of dystrophin in the smooth muscle of blood vessels is the major contributing factor to skeletal muscle pathogenesis in DMD and not the dystrophin deficiency in skeletal or cardiac muscle [21]. Dystrophin is expressed in the tunica media of blood vessels, especially in the muscular arteries. It has also been reported that the blood vesselassociated dystrophin is encoded by another gene than the skeletal muscle dystrophin gene [22]. In a mdx mice model study, it was shown that dystrophin which was absent in the blood vessels could be restored by induced genetic expression of full-length human dystrophin (hdys) and this expression was able to restore the NO-dependent attenuation of α -adrenergic vasoconstriction in the exercising muscles, preventing further exacerbation of muscle fibre necrosis [23]. In the present study, an increase in the plasma levels of dystrophin, which must have been derived from vascular smooth muscle is evidence for the efficacy of beta glucans as a potential adjunct to restore dystrophin in DMD. Other biochemical markers of relevance: While haptoglobin and urine myoglobin did not show significant differences, the increase in urine myoglobin in the N-163 Steroid +ve group deserves more analysis concerning the underlying mechanism. Greater activity among steroid-treated individuals may place their dystrophin-deficient muscles under greater mechanical stress, predisposing them to further muscle fibre damage and consequent myoglobinuria [24]. While titin and cystatin C decreased in the N-163 steroid +ve group and in the control Steroid +ve group, there was an increase in CK, which is paradoxical, as reports suggest that titin concentration correlates significantly with serum CK concentration [25]. Muscle strength evaluation: There were three evaluations to assess muscle strength and tone, done in a blinded manner by the same physiotherapist at baseline and post intervention.

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

Though the 6MWT and NSAA did not show any significant differences between the groups, MRC grading showed improvement of muscle strength in 67% of the subjects in the treatment group compared to 44% subjects in the control group, which is significant. The limitation of this being a 45-day study is relevant to the muscle-strength and functional evaluations, mandating the need for a longer study and follow-up duration. However, though small, the improvement in MRC grading at 45 days could be again attributed to the immune modulation effects of this disease-modifying supplement. The study shows proof of concept that DMD could be tackled by the N-163 beta glucan from three aspects: decrease in inflammation shown by decreased IL-6 and TNF-α, decrease in fibrosis evident by decreased TGF-β and IL-13 and, more importantly, restoration of dystrophin evident from a 32.8% increase in dystrophin levels. These effects hold regardless of the use or non-use of steroids, which is important, as this safety-proven food supplement can help DMD patients regardless of steroid status. Chronic inflammation being common to pathogenesis of all muscular dystrophies, immunomodulatory treatment may benefit patients with diverse types of muscular dystrophy [26]. Further, modulating the inflammatory response and inducing immunological tolerance to de novo dystrophin expression is critical to the success of dystrophin-replacement therapies [27]. The need to evaluate the muscles involved in respiratory function and myocardium should be mentioned here, as they are the cause of mortality in most of the DMD patients [1]. Though other dystrophies, such as limb girdle muscular dystrophy (LGMD), do not involve respiratory or cardiac muscles, inflammatory overactivity is the common pathophysiology among types of muscular dystrophy [26]. Once proven efficacious for DMD, extending the beneficial application of the N-163 beta glucans to other dystrophies such as LGMD can be considered.

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

DMD is a rare genetic disease with a maximum life expectancy of up to fourth decade, with the majority of victims dying in their late twenties to thirties. The average lifespan at birth, which was 20+ years for those born in or before 1970, has gradually increased by 10~15 years for those born and diagnosed with DMD in the 1980s and 1990s. This increase is attributed to better or early ventilatory assistance, steroid usage and cardiac care [28,29], which are only supportive interventions. With the gene therapies approved recently, there is a hope of additional progress and increase in lifespan [30]. Though these gene therapies (such as exon skipping) address the root cause by splicing out selected exons from the pre-mRNA at or next to the mutation site, generating a translatable transcript from the mutant dystrophin gene leading to dystrophin expression [30, 31], they are still marred by challenges such as delivery of gene-editing components throughout the musculature and mitigation of possible immune responses [32]. The current need, therefore, is to modulate the immune system and control the inflammation and ensuing fibrosis to delay the progression of the disease. The earlier usage of steroids in a regular manner was later changed to intermittent usage [33] with regimens varying between institutes; now, newer steroids with lesser adverse effects are in various stages of progress towards clinical applications [34]. In this background, the safety of this N-163-produced beta glucan food supplement without adverse reactions is to be considered an indispensable value addition. Targeting the inflammation component (the criteria for selecting this supplement for this study) having yielded beneficial outcomes, additional studies on this characteristic could be of value to possibly extending their application for other neuroinflammatory diseases, such as multiple sclerosis. The limitations of the study include uneven distribution of subjects, broad age range (5-19 years) and short follow-up (only 45 days); improvements in muscle function over the course of the study showed variability that may have been due to the level of sensitivity to change of functional assessments during the disease progression in the age group. Among the 27

subjects, two-thirds were ambulatory and the remaining non-ambulatory; the evaluation criteria differences must be kept in mind, which may show equivalent quantification among all DMD patients at different stages of disease severity when non-invasive myograms to measure the individual muscles accurately could be undertaken. Further, the steroid dose was not uniform and fell into a broad range (6-24 mg). Also, the consumption of steroids vs those who did not consume them or those who had stopped steroids after an initial duration of consumption, as well as regimen variation, are to be considered while interpreting the outcomes. All these aspects mandate the need for larger randomized clinical trials of longer duration to validate this supplement as a treatment.

Conclusion:

N-163 beta glucan with and without steroids helped decrease IL-6, TGF-β and IL-13 and increase dystrophin levels along with improvement of muscle strength in subjects with DMD in this clinical study. Thus, N-163 beta glucan is a safe and effective potential therapeutic adjunct for patients with DMD. While the benefits documented may help slow the rate of progression of this devastating disease, confirmation by longer and larger studies will help establish this agent for routine clinical application as a disease-modifying agent with the potential to help prolong the lifespan of DMD patients. After such validation, extending its application to other dystrophies such as LGMD could be considered, and further in-depth research in neuroinflammatory diseases are likely to shed light on the mechanism of action, leading to additional beneficial applications.

416 417 418 419 **Abbreviations:** 420 DMD: Duchenne muscular dystrophy 421 CK: Creatinine kinase 422 TNF-α: tumour necrosis factor - Alpha 423 MRC: Medical research council 424 NLR: Neutrophil-to-lymphocyte ratio 425 LCR: Lymphocyte-to-CRP ratio 426 LeCR: Leukocyte-to-CRP ratio 427 NASH: Non-alcoholic steatohepatitis 428 6MWT: Six-minute walk test 429 NSAA: North Star Ambulatory Assessment 430 LGMD: Limb girdle muscular dystrophy 431 432 **References:** 433 1. Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, Jones K, Krishnamurthi R, Feigin V. Prevalence of muscular dystrophies: a systematic 434 435 literature review. Neuroepidemiology. 2014;43(3-4):259-68. 436 2. Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O, Fischer D. 437 Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Trials. 438 439 2019;20(1):637.

- 440 3. Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield
- LM, Woodcock J. Immune-mediated pathology in Duchenne muscular dystrophy. Sci
- 442 Transl Med. 2015;7(299):299rv4.
- 4. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for
- Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD003725.
- 5. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Spotlight on
- Research: Optimizing Steroid Treatment for Duchenne Muscular Dystrophy
- 447 https://www.niams.nih.gov/newsroom/spotlight-on-research/optimizing-steroid-
- 448 <u>treatment-duchenne-muscular-dystrophy</u> (Accessed: December 13, 2021).
- 6. Licitra R, Marchese M, Brogi L, Fronte B, Pitto L, Santorelli FM. Nutraceutical
- Screening in a Zebrafish Model of Muscular Dystrophy: Gingerol as a Possible Food
- 451 Aid. Nutrients. 2021;13(3):998.
- 7. Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R,
- 453 Preethy S, Abraham SJK. Immune and metabolic beneficial effects of Beta 1,3-1,6
- 454 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-
- 455 aged Japanese men: An exploratory study. medRxiv 2021.08.05.21261640; doi:
- 456 10.1101/2021.08.05.21261640
- 8. Ikewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan
- 458 M, Vaddi S, Senthilkumar R, Preethy S, Abraham SJK. Beneficial effects of the AFO-
- 459 202 and N-163 strains of Aureobasidium pullulans produced 1,3-1,6 beta glucans on
- 460 non-esterified fatty acid levels in obese diabetic KKAy mice: A comparative
- 461 study.bioRxiv 2021.07.22.453362; doi: 10.1101/2021.07.22.453362
- 9. Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya VD, Vaddi S,
- Senthilkumar R, Levy GA, Abraham SJK. Hepatoprotective effects of Aureobasidium
- 464 pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM-

- animal model of non-alcoholic steatohepatitis. bioRxiv 2021.07.08.451700; doi:
- 466 10.1101/2021.07.08.451700
- 467 10. MRC Muscle Scale. https://mrc.ukri.org/research/facilities-and-resources-for-
- 468 researchers/mrc-scales/mrc-muscle-scale/ (Accessed: December 13, 2021).
- 469 11. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL,
- 470 Atkinson L, Reha A, Hirawat S, Miller LL. The 6-minute walk test as a new outcome
- 471 measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41(4):500-10
- 12. Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, Manzur A, Muntoni F;
- 473 North Star Clinical Network for Paediatric Neuromuscular Disease. Development of a
- functional assessment scale for ambulatory boys with Duchenne muscular dystrophy.
- 475 Physiother Res Int. 2012;17(2):101-9. doi: 10.1002/pri.520.
- 476 13. Stephenson KA, Rae MG, O'Malley D. Interleukin-6: A neuro-active cytokine
- contributing to cognitive impairment in Duchenne muscular dystrophy? Cytokine.
- 478 2020;133:155134.
- 479 14. Mammen AL, Sartorelli V. IL-6 Blockade as a Therapeutic Approach for Duchenne
- 480 Muscular Dystrophy. EBioMedicine. 2015;2(4):274-5.
- 481 15. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, Muñoz-
- 482 Cánoves P. Aberrant repair and fibrosis development in skeletal muscle. Skelet
- 483 Muscle. 2011;1(1):21.
- 484 16. Ceco E, McNally EM. Modifying muscular dystrophy through transforming growth
- 485 factor-β. FEBS J. 2013;280(17):4198-209.
- 486 17. Pelosi L, Berardinelli MG, De Pasquale L, Nicoletti C, D'Amico A, Carvello F,
- 487 Moneta GM, Catizone A, Bertini E, De Benedetti F, Musarò A. Functional and
- 488 Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor
- 489 Blockade. EBioMedicine. 2015 Feb 26;2(4):285-93.

- 18. Shimizu-Motohashi Y, Komaki H, Motohashi N, Takeda S, Yokota T, Aoki Y.
- 491 Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of
- Therapeutic Approaches. J Pers Med. 2019;9(1):1.
- 493 19. Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, Clark
- 494 KR. Gene therapy for muscular dystrophy: lessons learned and path forward.
- 495 Neurosci Lett. 2012;527(2):90-9.
- 496 20. Wells DJ. What is the level of dystrophin expression required for effective therapy of
- 497 Duchenne muscular dystrophy? J Muscle Res Cell Motil. 2019;40(2):141-150.
- 498 21. Gajendran, N. The root cause of Duchenne muscular dystrophy is the lack of
- dystrophin in smooth muscle of blood vessels rather than in skeletal muscle per se
- 500 F1000Research 2018; 7: 1321.
- 501 22. Augier N, Boucraut J, Léger J, Anoal M, Nicholson LV, Voelkel MA, Léger JJ,
- Pellissier JF. A homologue of dystrophin is expressed at the blood vessel membrane
- of DMD and BMD patients: immunological evidence. J Neurol Sci. 1992
- Feb;107(2):233-8.
- 505 23. Ito K, Kimura S, Ozasa S, Matsukura M, Ikezawa M, Yoshioka K, Ueno H, Suzuki
- M, Araki K, Yamamura K, Miwa T, Dickson G, Thomas GD, Miike T. Smooth
- 507 muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
- 508 Hum Mol Genet. 2006 Jul 15;15(14):2266-75.
- 509 24. Awano H, Matsumoto M, Nagai M, Shirakawa T, Maruyama N, Iijima K, Nabeshima
- 510 YI, Matsuo M. Diagnostic and clinical significance of the titin fragment in urine of
- 511 Duchenne muscular dystrophy patients. Clin Chim Acta. 2018;476:111-116.
- 512 25. Garrood P, Eagle M, Jardine PE, Bushby K, Straub V. Myoglobinuria in boys with
- 513 Duchenne muscular dystrophy on corticosteroid therapy. Neuromuscul Disord. 2008
- 514 ;18(1):71-3.

- 515 26. Raimondo TM, Mooney DJ. Anti-inflammatory nanoparticles significantly improve
- muscle function in a murine model of advanced muscular dystrophy. Sci Adv.
- 517 2021;7(26):eabh3693.
- 518 27. Thomas GD, Ye J, De Nardi C, Monopoli A, Ongini E, Victor RG. Treatment with a
- 519 nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse
- model of Duchenne muscular dystrophy. PLoS One. 2012;7(11):e49350.
- 521 28. Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M,
- 522 Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular
- dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79
- 29. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, Perrouin Verbe B.
- 525 Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM
- Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med.
- 527 2013;56(6):443-54.
- 30. Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular
- 529 Dystrophy. Mol Ther. 2018;26(10):2337-2356.
- 31. Echevarría L, Aupy P, Govenvalle A. Exon-skipping advances for Duchenne
- muscular dystrophy. Hum Mol Genet. 2018;27(R2):R163-R172.
- 32. Dzierlega K, Yokota T. Optimization of antisense-mediated exon skipping for
- 533 Duchenne muscular dystrophy. Gene Ther. 2020;27(9):407-416. doi: 10.1038/s41434-
- 534 020-0156-6.
- 535 33. Olson EN. Toward the correction of muscular dystrophy by gene editing. Proc Natl
- 536 Acad Sci U S A. 2021;118(22):e2004840117.
- 34. Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D, Rybalka E.
- Standard of care versus new-wave corticosteroids in the treatment of Duchenne

muscular dystrophy: Can we do better? Orphanet J Rare Dis. 2021;16(1):117. doi: 10.1186/s13023-021-01758-9. 35. Boziki MK, Kesidou E, Theotokis P, Mentis AA, Karafoulidou E, Melnikov M, Sviridova A, Rogovski V, Boyko A, Grigoriadis N. Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know. Brain Sci. 2020;10(4):234. 36. Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Kandaswamy R, Senthilkumar R, Preethy S, Abraham SJK. Beneficial reconstitution of gut microbiota and control of alpha-synuclein and curli-amyloidsproducing enterobacteria, by beta 1,3-1,6 glucans in a clinical pilot study of autism and potentials in neurodegenerative diseases. medRxiv 2021.10.26.21265505; doi: 10.1101/2021.10.26.21265505

Tables and Figures

Table 1: Demographics and baseline characteristics

Control Steroid -ve	Subject	Age in years	Weight in kgs	Exon Deletion	Clinical Diagnosis	Ambulatory/ Non- Ambulatory	Dose of Deflaz acort (mg/da y)	Duration of consump tion of steroids
	1	6-10	12	10 & 11	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	2	6-10	27	46-55	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	3	16-20	48		Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	4	11-15	60	8 to 48	Duchenne Muscular Dystrophy	Non- Ambulatory	NA	NA

					(DMD)			
	5	11-15	55	10- 11/Dup	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	1	16-20	65	44	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	6	8 years
Control Steroid	2	6-10	25	5 & 6	Duchenne Muscular Dystrophy (DMD)	Ambulatory	12	2.5 months
+ve	3	6-10	21	49-52	Duchenne Muscular Dystrophy (DMD)	Ambulatory	9	11 months
	4	11-15	48	52	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	6 years
	1	6-10	28	48-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
N-163 Steroid -ve	2	1-5	10	45-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	3	11-15	38	45-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	4	6-10	45	60	Becker muscular dystrophy (BMD)	Ambulatory	NA	NA
	5	6-10	39	10-11/ Dup	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	6	6-10	21	49-52	Duchenne Muscular	Ambulatory	NA	NA

					Dystrophy (DMD)			
	7	11-15	39	43	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	8	11-15	40		Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	NA	NA
	9	6-10	22	44- 57/Dup	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	1	1-5	18	48-50	Duchenne Muscular Dystrophy (DMD)	Non- Ambulatory	6	5 months
	2	11-15	59	17	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	2 months
N-163 Steroid +ve	3	11-15	40	60	Becker muscular dystrophy (BMD)	Ambulatory	6	6 years
	4	6-10	20	48-52	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	3 years
	5	6-10	36	48-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	3 years

Table 2: Details of the ELISA kits along with their sensitivity

S.No	Human Antibody	Purchased from	Catalogue No.	Limit of detection/Sensitivity
1	Interleukin-6 (IL6)	Seimens	10995080	3.0 pg/mL
2	Myoglobin	Diagnostic Automation Inc	1667-18	270 pg/mL
3	Dystrophin (DMD)	KINESISDx	K12-1446	0.042 ng/mL
4	Titin (TTN)	Mybiosource	MBS762344	0.094 ng/mL
5	Creatinine Kinase (CK)	Agappe	51404001	2.0 U/L
6	IL-13	Diaclone	850080048	1.5 pg/mL
7	TGF-β	Diaclone	650010096	8.6 pg/mL
8	Cystatin C	Siemens	E0001V	$0.06~\mu \mathrm{g/L}$
9	TNF-a	Siemens	LKNF1	6.23 pg/mL
10	Haptoglobin	Seimens	OSAV09	0.26 ng/mL

Table 3: Medical research council (MRC) grading of muscle power in the study groups

Subject	Ambulatory/Non- ambulatory	Baseline	Post-intervention	Progression					
Control group									
1	Ambulatory	151	165	Improved					
2	Ambulatory	133	162	Improved					
3	Non-ambulatory	70	80	Improved					
4	Non-ambulatory	164	164	No change					
5	Non-ambulatory	109	106	Worsened					
6	Non-ambulatory	102	105	Improved					
7	Non-ambulatory	117	115	Worsened					
8	Non-ambulatory	110	109	No change					
9	Non-ambulatory	105	102	Worsened					
1	Ambulatory	134	133	Worsened					
1	Ambulatory	134	133	Worsened					
2	Ambulatory	146	163	Improved					
3	Ambulatory	119	131	Improved					
4	Ambulatory	127	136	Improved					
5	Ambulatory	154	160	Improved					
6	Ambulatory	158	168	Improved					
7	Non-ambulatory	102	119	Improved					
8	Non-ambulatory	116	117	Improved					
9	Non-ambulatory	127	127	No change					
10	Non-ambulatory	120	131	Improved					
11	Non-ambulatory	96	107	Improved					
12	Non-ambulatory	111	122	Improved					

13	Non-ambulatory	117	113	Worsened	
14	Non-ambulatory	108	108	No change	
15	Non-ambulatory	103	107	Improved	
16	Non-ambulatory	145	148	Improved	
17	Non-ambulatory	93	119	Improved	
18	Non-ambulatory	Test couldn't be performed			

605 Figures:




Figure 1: CONSORT flow diagram of the trial




Figure 2: IL-6 showed the most significant decrease in the N-163 Steroid -ve group compared

to other groups. (*p-value significance < 0.05)

608




Figure 3: Levels of IL-13 levels showed statistically significant increase in control groups and decrease in treatment groups (*p-value significance < 0.05)




Figure 4: Levels of TGF- β showed significant decrease in the N-163 Steroid -ve group compared to other groups (*p-value significance < 0.05)




Figure 5: Levels of dystrophin showed significant increase in the N-163 Steroid -ve group compared to other groups (*p-value significance < 0.05)




Figure 6: Comprehensive figure of IL-6, IL-13, TGF- β and Dystrophin showing comparison of values between control and treatment group (N-163), pre- and post-intervention (*p-value significance < 0.05)




Figure 7: Levels of Creatinine kinase (CK), Titin, Cystatic-C, Urine myoglobin, Haptoglobin

and TNF- α between control and treatment group (N-163), pre- and post-intervention (*p-value significance < 0.05)




Figure 8: MRC muscle grading, 6MWT and NSAA results between control and treatment group (N-163), pre- and post-intervention (*p-value significance < 0.05)